Immunogenomics: using genomics to personalize cancer immunotherapy

Virchows Archiv : an International Journal of Pathology
Rance C Siniard, Shuko Harada

Abstract

While the use of genomic data has the potential to revolutionize patient care, there is still much work to be done with regard to the transformation of host-tumor interactions into favorable clinical outcomes for our patients. High-throughput technologies, such as next-generation sequencing (NGS), have rapidly advanced our understanding of oncology, and we are learning that most tumors do not simply possess consistently mutated genes that are responsible for tumorigenesis, facilitating the need for personalized cancer therapy. A T cell-dependent mechanism of cancer progression was discovered in 2012, providing a potential link to cancer immunotherapy. Since then, an antibody against cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), ipilimumab, and three programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors, pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq), were approved by the Food and Drug Administration (FDA) in the USA. In this review article, based on evidence that has been emerging in the literature over the last decade, we will discuss the basis for including genomic data in immunotherapy regimens, the current progress in identifying biomarkers targetable by immune checkpoin...Continue Reading

References

Apr 2, 1999·Immunology and Cell Biology·K D McCoy, G Le Gros
Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Nov 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Audrey L KinterAnthony S Fauci
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher G WillettRakesh K Jain
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Nov 16, 2010·Seminars in Oncology·Axel HoosRachel Humphrey
Jan 13, 2012·Current Opinion in Immunology·Suzanne L TopalianDrew M Pardoll
Jan 18, 2012·Molecular Oncology·Thomas F Gajewski
Feb 10, 2012·Nature·Hirokazu MatsushitaRobert D Schreiber
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Aug 11, 2012·Cancer Immunology, Immunotherapy : CII·Saskia J A M SantegoetsTanja D de Gruijl
Sep 6, 2012·International Journal of Cancer. Journal International Du Cancer·Ben TranJanet E Dancey
Sep 8, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Serena S KwekLawrence Fong
Mar 30, 2013·Science·Bert VogelsteinKenneth W Kinzler
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nienke van RooijTon N Schumacher
Oct 3, 2013·Scientific Reports·David TamboreroNuria Lopez-Bigas
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Apr 9, 2014·Cancer Immunology, Immunotherapy : CII·George C PrendergastAlexander J Muller
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Apr 30, 2014·Cancer Immunology Research·Derek Ng TangPadmanee Sharma
May 7, 2014·The Oncologist·Maria SchwaederleRazelle Kurzrock
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 31, 2015·The New England Journal of Medicine·Francis S Collins, Harold Varmus

❮ Previous
Next ❯

Citations

Dec 8, 2017·Nature Reviews. Rheumatology·Andrew P CopeUNKNOWN RA-MAP Consortium
Apr 3, 2020·Expert Review of Vaccines·Vaishali Y Londhe, Varada Date
Jul 23, 2020·Frontiers in Chemistry·Shuang YueShuang Wei
Nov 30, 2018·Chemical Reviews·Bernhard EnglingerWalter Berger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.